Miral, Silverio C.
HRN: 04-04-88 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/08/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
11/08/2022
11/15/2022
IV
500mg
Q8
AGE With Severe Dhn
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes